Nabriva Therapeutics plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income, net
Non-cash interest income
Non-cash interest expense
Loss on extinguishment of debt
Loss on inventory commitments
Depreciation and amortization expense
Amortization of right-of-use assets
Stock-based compensation
In-process research and development in connection with acquisition
Other

Changes in operating assets and liabilities:
Changes in other receivables
(Increase) decrease in other non-current assets
(Increase) decrease in accounts receivable, net and other receivables and prepaid expenses
(Increase) decrease in inventory
Increase (decrease) in accounts payable
Increase in accrued expenses and other liabilities
Increase (decrease) in deferred revenue
Decrease in other non-current liabilities
Increase (decrease) in income tax liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of equipment and intangible assets
Purchases of term deposits
Changes in restricted cash
Transaction costs related to Zavante acquisition, net of cash acquired
Other
Net cash used in investing activities

Cash flows from financing activities
Proceeds from exercise of warrants
Proceeds from issuance of ordinary shares and warrants
Proceeds from at-the-market facility
July 2018 public offering
At-the-market offering
Total proceeds from at-the-market facility

Proceeds from long-term debt, net of issuance costs
Debt transaction costs
Proceeds from employee stock purchase plan
Repayments of long-term borrowings
Repayments of warrants
Equity transaction costs
Net cash provided by financing activities

Effects of exchange rate changes on the balance of cash held in foreign currencies
Net increase/(decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosure of cash flow information:
Interest paid
Taxes paid
Equity transaction costs included in accounts payable and accrued expenses

Comments